GraceSaw
2021-06-19
[Strong]
BioNTech shots have stronger antibody response than Sinovac, Hong Kong study shows - SCMP
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
39
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":165153029,"tweetId":"165153029","gmtCreate":1624109311761,"gmtModify":1631889755638,"author":{"id":3560390927109287,"idStr":"3560390927109287","authorId":3560390927109287,"authorIdStr":"3560390927109287","name":"GraceSaw","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[Strong] </span><br></p></body></html>","htmlText":"<html><head></head><body><p><span>[Strong] </span><br></p></body></html>","text":"[Strong]","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":39,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/165153029","repostId":2144703352,"repostType":2,"repost":{"id":"2144703352","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1624078758,"share":"https://www.laohu8.com/m/news/2144703352?lang=&edition=full","pubTime":"2021-06-19 12:59","market":"sh","language":"en","title":"BioNTech shots have stronger antibody response than Sinovac, Hong Kong study shows - SCMP","url":"https://stock-news.laohu8.com/highlight/detail?id=2144703352","media":"Reuters","summary":"June 19 (Reuters) - People who are vaccinated against COVID-19 with BioNTech's vaccine were found","content":"<html><body><p>June 19 (Reuters) - People who are vaccinated against COVID-19 with BioNTech's vaccine were found to have \"substantially higher\" levels of antibodies than those who received Sinovac's jab, the South China Morning Post reported </p><p>on Saturday, citing a Hong Kong study.</p><p> Some who received the Sinovac vaccine might need a third booster shot as well, the newspaper said, citing lead researcher Professor Benjamin Cowling, an epidemiologist with the University of Hong Kong (HKU).</p><p> The government-commissioned study was conducted by HKU's school of public health and involved tracking the antibody responses of 1,000 people who received either vaccine, the report added.</p><p> Earlier this week, officials in Indonesia warned that more than 350 medical workers have caught COVID-19 despite being vaccinated with Sinovac and dozens have been hospitalised, raising concerns about its efficacy against more infectious variants of the virus.</p><p> Earlier in June, Uruguay released real-world data on the impact of Sinovac Biotech's COVID-19 vaccine among its population that showed it was over 90% effective in preventing intensive care admissions and deaths. </p><p> The Uruguay government also studied the effectiveness of the Pfizer/BioNTech's vaccine among 162,047 health workers and people over 80 years old, and said the shot was 94% effective at preventing intensive care unit admissions and deaths, and reduced infections by 78%.</p><p> (Reporting by Nandakumar D in Bengaluru; Editing by Raju Gopalakrishnan)</p><p>((Nandakumar.D@thomsonreuters.com; Outside U.S. +91 9677690635;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech shots have stronger antibody response than Sinovac, Hong Kong study shows - SCMP</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech shots have stronger antibody response than Sinovac, Hong Kong study shows - SCMP\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-06-19 12:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>June 19 (Reuters) - People who are vaccinated against COVID-19 with BioNTech's vaccine were found to have \"substantially higher\" levels of antibodies than those who received Sinovac's jab, the South China Morning Post reported </p><p>on Saturday, citing a Hong Kong study.</p><p> Some who received the Sinovac vaccine might need a third booster shot as well, the newspaper said, citing lead researcher Professor Benjamin Cowling, an epidemiologist with the University of Hong Kong (HKU).</p><p> The government-commissioned study was conducted by HKU's school of public health and involved tracking the antibody responses of 1,000 people who received either vaccine, the report added.</p><p> Earlier this week, officials in Indonesia warned that more than 350 medical workers have caught COVID-19 despite being vaccinated with Sinovac and dozens have been hospitalised, raising concerns about its efficacy against more infectious variants of the virus.</p><p> Earlier in June, Uruguay released real-world data on the impact of Sinovac Biotech's COVID-19 vaccine among its population that showed it was over 90% effective in preventing intensive care admissions and deaths. </p><p> The Uruguay government also studied the effectiveness of the Pfizer/BioNTech's vaccine among 162,047 health workers and people over 80 years old, and said the shot was 94% effective at preventing intensive care unit admissions and deaths, and reduced infections by 78%.</p><p> (Reporting by Nandakumar D in Bengaluru; Editing by Raju Gopalakrishnan)</p><p>((Nandakumar.D@thomsonreuters.com; Outside U.S. +91 9677690635;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","SVA":"科兴生物"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144703352","content_text":"June 19 (Reuters) - People who are vaccinated against COVID-19 with BioNTech's vaccine were found to have \"substantially higher\" levels of antibodies than those who received Sinovac's jab, the South China Morning Post reported on Saturday, citing a Hong Kong study. Some who received the Sinovac vaccine might need a third booster shot as well, the newspaper said, citing lead researcher Professor Benjamin Cowling, an epidemiologist with the University of Hong Kong (HKU). The government-commissioned study was conducted by HKU's school of public health and involved tracking the antibody responses of 1,000 people who received either vaccine, the report added. Earlier this week, officials in Indonesia warned that more than 350 medical workers have caught COVID-19 despite being vaccinated with Sinovac and dozens have been hospitalised, raising concerns about its efficacy against more infectious variants of the virus. Earlier in June, Uruguay released real-world data on the impact of Sinovac Biotech's COVID-19 vaccine among its population that showed it was over 90% effective in preventing intensive care admissions and deaths. The Uruguay government also studied the effectiveness of the Pfizer/BioNTech's vaccine among 162,047 health workers and people over 80 years old, and said the shot was 94% effective at preventing intensive care unit admissions and deaths, and reduced infections by 78%. (Reporting by Nandakumar D in Bengaluru; Editing by Raju Gopalakrishnan)((Nandakumar.D@thomsonreuters.com; Outside U.S. +91 9677690635;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":401,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/165153029"}
精彩评论